Talat Imran
2022
In 2022, Talat Imran earned a total compensation of $4.3M as Chief Executive Officer at Rani Therapeutics Holdings, a 63% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $312,000 |
|---|---|
| Option Awards | $2,340,204 |
| Salary | $515,000 |
| Stock Awards | $1,143,986 |
| Total | $4,311,190 |
Imran received $2.3M in option awards, accounting for 54% of the total pay in 2022.
Imran also received $312K in non-equity incentive plan, $515K in salary and $1.1M in stock awards.
Rankings
In 2022, Talat Imran's compensation ranked 781st out of 5,625 executives tracked by ExecPay. In other words, Imran earned more than 86.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 781 out of 5,625 | 86th |
Division Manufacturing | 354 out of 3,053 | 88th |
Major group Chemicals And Allied Products | 117 out of 1,380 | 92nd |
Industry group Drugs | 104 out of 1,281 | 92nd |
Industry Pharmaceutical Preparations | 76 out of 927 | 92nd |
Source: SEC filing on April 11, 2023.
Imran's colleagues
We found two more compensation records of executives who worked with Talat Imran at Rani Therapeutics Holdings in 2022.